Byooviz

Byooviz is a brand of ranibizumab, a monoclonal antibody fragment used in the management of several retinal conditions that affect vision. Ranibizumab works by targeting vascular endothelial growth factor, commonly known as VEGF. VEGF plays a major role in the formation of abnormal blood vessels and fluid leakage inside the eye, which can damage the retina and lead to vision loss. By blocking VEGF activity, Byooviz helps reduce swelling, slow disease progression, and support visual stability.
Byooviz is mainly used for age-related macular degeneration, particularly the wet form, where fragile blood vessels grow beneath the retina. It is also used in diabetic macular edema, a condition caused by long-term diabetes that leads to fluid buildup in the macula, the central part of the retina responsible for sharp vision. Another important use is for macular edema following retinal vein occlusion, where blocked blood flow results in swelling and impaired sight.
Treatment with Byooviz focuses on maintaining vision and, in some cases, improving visual clarity. Results vary among individuals, depending on disease severity and response. Regular eye examinations are important to monitor progress and retinal health.
Possible unwanted effects include eye discomfort, redness, temporary blurred vision, or increased eye pressure. Serious complications such as infection or retinal damage are uncommon but require immediate medical attention. Overall, Byooviz plays a significant role in modern retinal care by helping protect vision and support daily visual function. It is widely recognized for its targeted action and consistent results in controlled clinical settings worldwide.